Chemokines and squamous cancer of the head and neck: targets for therapeutic intervention?

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• McMahon S, Chen AY. Head and neck cancer. Cancer Metastasis Rev.22(1), 21–24 (2003).
   PubMedGoogle Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet357(9255), 539–545 (2001).
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity12(2), 121–127 (2000).
   PubMed Web of Science ®Google Scholar
• Bacon K, Baggiolini M, Broxmeyer H et al. Chemokine/chemokine receptor nomenclature. J. Interferon Cytokine Res.22(10), 1067–1068 (2002).
   PubMed Web of Science ®Google Scholar
• Cocchi F, DeVico AL, Garzino-Demo A et al. Identification of RANTES, MIP-1 α, and MIP-1 β as the major HIV-suppressive factors produced by CD8+ T cells. Science270(5243), 1811–1815 (1995).
   PubMed Web of Science ®Google Scholar
• Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol.18, 217–242 (2000).
   PubMed Web of Science ®Google Scholar
• Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity16(1), 1–4 (2002).
   PubMed Web of Science ®Google Scholar
• Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol.22, 891–928 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson EK, Graham GJ, Daubersies P et al. Hemopoietic stem cell inhibitor (SCI/MIP-1 α) also inhibits clonogenic epidermal keratinocyte proliferation. J. Invest. Dermatol.101(2), 113–117 (1993).
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan G, Salgia R, Groopman JE. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J. Biol. Chem.275(10), 6868–6875 (2000).
   PubMed Web of Science ®Google Scholar
• Bonacchi A, Romagnani P, Romanelli RG et al. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J. Biol. Chem.276(13), 9945–9954 (2001).
   PubMedGoogle Scholar
• Chandrasekar B, Melby PC, Sarau HM et al. Chemokine–cytokine cross-talk. The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase–NF-κB pathway. J. Biol. Chem.278(7), 4675–4686 (2003).
   PubMedGoogle Scholar
• Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I κB kinase, and nuclear factor-κB and induces cell–cell adhesion and aortic smooth muscle cell proliferation. J. Biol. Chem.279(5), 3188–3196 (2004).
   PubMed Web of Science ®Google Scholar
• Schraufstatter IU, Chung J, Burger M. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am. J. Physiol. Lung Cell Mol. Physiol.280(6), L1094–L1103 (2001).
   PubMed Web of Science ®Google Scholar
• Wang D, Sai J, Carter G et al. PAK1 kinase is required for CXCL1-induced chemotaxis. Biochemistry41(22), 7100–7107 (2002).
   PubMedGoogle Scholar
• Tan W, Martin D, Gutkind JS. The Gα13-Rho signaling axis is required for SDF-1-induced migration through CXCR4. J. Biol. Chem.281(51), 39542–39549 (2006).
   PubMed Web of Science ®Google Scholar
• Liu-Bryan R, Pay S, Schraufstatter IU, Rose DM. The CXCR1 tail mediates β1 integrin-dependent cell migration via MAP kinase signaling. Biochem. Biophys. Res. Commun.332(1), 117–125 (2005).
   PubMedGoogle Scholar
• Van Damme J, Struyf S, Opdenakker G. Chemokine-protease interactions in cancer. Semin. Cancer Biol.14(3), 201–208 (2004).
   PubMedGoogle Scholar
• Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol.72(1), 9–18 (2002).
   PubMed Web of Science ®Google Scholar
• Balentien E, Mufson BE, Shattuck RL, Derynck R, Richmond A. Effects of MGSA/GRO α on melanocyte transformation. Oncogene6(7), 1115–1124 (1991).
   PubMedGoogle Scholar
• Zhou Y, Zhang J, Liu Q et al. The chemokine GRO-α (CXCL1) confers increased tumorigenicity to glioma cells. Carcinogenesis26(12), 2058–2068 (2005).
   PubMedGoogle Scholar
• Robinson S, Tani M, Strieter RM, Ransohoff RM, Miller RH. The chemokine growth-regulated oncogene-α promotes spinal cord oligodendrocyte precursor proliferation. J. Neurosci.18(24), 10457–10463 (1998).
   PubMedGoogle Scholar
• Wu Q, Miller RH, Ransohoff RM et al. Elevated levels of the chemokine GRO-1 correlate with elevated oligodendrocyte progenitor proliferation in the jimpy mutant. J. Neurosci.20(7), 2609–2617 (2000).
   PubMedGoogle Scholar
• Tsai HH, Frost E, To V et al. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell110(3), 373–383 (2002).
   PubMed Web of Science ®Google Scholar
• Metzner B, Hofmann C, Heinemann C et al. Overexpression of CXC-chemokines and CXC-chemokine receptor type II constitute an autocrine growth mechanism in the epidermoid carcinoma cells KB and A431. Oncol. Rep.6(6), 1405–1410 (1999).
   PubMed Web of Science ®Google Scholar
• Wang B, Hendricks DT, Wamunyokoli F, Parker MI. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res.66(6), 3071–3077 (2006).
   PubMed Web of Science ®Google Scholar
• Feng G, Ohmori Y, Chang PL. Production of chemokine CXCL1/KC by okadaic acid through the nuclear factor-κB pathway. Carcinogenesis27(1), 43–52 (2006).
   PubMedGoogle Scholar
• Dhawan P, Richmond A. A novel NF-κB-inducing kinase–MAPK signaling pathway up-regulates NF-κB activity in melanoma cells. J. Biol. Chem.277(10), 7920–7928 (2002).
   PubMed Web of Science ®Google Scholar
• Amiri KI, Ha HC, Smulson ME, Richmond A. Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP–ribose) polymerase-1. Oncogene25(59), 7714–7722 (2006).
   PubMedGoogle Scholar
• Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature410(6824), 50–56 (2001).
   PubMed Web of Science ®Google Scholar
• Miller LJ, Kurtzman SH, Wang Y et al. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res.18(1A), 77–81 (1998).
   PubMed Web of Science ®Google Scholar
• Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol.14(3), 171–179 (2004).
   PubMed Web of Science ®Google Scholar
• Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res.62(24), 7203–7206 (2002).
   PubMed Web of Science ®Google Scholar
• Brown MJ, Nijhara R, Hallam JA et al. Chemokine stimulation of human peripheral blood T lymphocytes induces rapid dephosphorylation of ERM proteins, which facilitates loss of microvilli and polarization. Blood102(12), 3890–3899 (2003).
   PubMed Web of Science ®Google Scholar
• Singh S, Singh UP, Grizzle WE, Lillard JW Jr. CXCL12–CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab. Invest.84(12), 1666–1676 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang J, Sarkar S, Yong VW. The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase. Carcinogenesis26(12), 2069–2077 (2005).
   PubMed Web of Science ®Google Scholar
• Murakami T, Cardones AR, Finkelstein SE et al. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J. Exp. Med.198(9), 1337–1347 (2003).
   PubMedGoogle Scholar
• Simonetti O, Goteri G, Lucarini G et al. Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur. J. Cancer42(8), 1181–1187 (2006).
   PubMed Web of Science ®Google Scholar
• Moskovits N, Kalinkovich A, Bar J, Lapidot T, Oren M. p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res.66(22), 10671–10676 (2006).
   PubMed Web of Science ®Google Scholar
• Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science262(5142), 1980–1981 (1993).
   PubMed Web of Science ®Google Scholar
• Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle5(15), 1597–1601 (2006).
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell121(3), 335–348 (2005).
   PubMed Web of Science ®Google Scholar
• Kurose K, Gilley K, Matsumoto S et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet.32(3), 355–357 (2002).
   PubMed Web of Science ®Google Scholar
• Paterson RF, Ulbright TM, MacLennan GT et al. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer98(9), 1830–1836 (2003).
   PubMedGoogle Scholar
• Wong CW, Lee A, Shientag L et al. Apoptosis: an early event in metastatic inefficiency. Cancer Res.61(1), 333–338 (2001).
   PubMed Web of Science ®Google Scholar
• Kassenbrock CK, Hunter S, Garl P, Johnson GL, Anderson SM. Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor. J. Biol. Chem.277(28), 24967–24975 (2002).
   PubMedGoogle Scholar
• Swan EA, Jasser SA, Holsinger FC et al. Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol.39(7), 648–655 (2003).
   PubMedGoogle Scholar
• Sanchez-Sanchez N, Riol-Blanco L, De La Rosa G et al. Chemokine receptor CCR7 Induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood104, 619–625 (2004).
   PubMedGoogle Scholar
• Carmeliet P. Angiogenesis in life, disease and medicine. Nature438(7070), 932–936 (2005).
   PubMed Web of Science ®Google Scholar
• Koch AE, Polverini PJ, Kunkel SL et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science258(5089), 1798–1801 (1992).
   PubMed Web of Science ®Google Scholar
• Lin EY, Li JF, Gnatovskiy L et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res.66(23), 11238–11246 (2006).
   PubMed Web of Science ®Google Scholar
• Heidemann J, Ogawa H, Dwinell MB et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem.278(10), 8508–8515 (2003).
   PubMed Web of Science ®Google Scholar
• Sodhi A, Montaner S, Patel V et al. Akt plays a central role in sarcomagenesis induced by Kaposi’s sarcoma herpesvirus-encoded G protein-coupled receptor. Proc. Natl Acad. Sci. USA101(14), 4821–4826 (2004).
   PubMed Web of Science ®Google Scholar
• Sun Q, Matta H, Lu G, Chaudhary PM. Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-κB activation. Oncogene25(19), 2717–2726 (2006).
   PubMed Web of Science ®Google Scholar
• Strieter RM, Belperio JA, Phillips RJ, Keane MP. CXC chemokines in angiogenesis of cancer. Semin. Cancer Biol.14(3), 195–200 (2004).
   PubMed Web of Science ®Google Scholar
• Romagnani P, Annunziato F, Lasagni L et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest.107(1), 53–63 (2001).
   PubMed Web of Science ®Google Scholar
• Lasagni L, Francalanci M, Annunziato F et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med.197(11), 1537–1549 (2003).
   PubMed Web of Science ®Google Scholar
• Shintani S, Ishikawa T, Nonaka T et al. Growth-regulated oncogene-1 expression is associated with angiogenesis and lymph node metastasis in human oral cancer. Oncology66(4), 316–322 (2004).
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Patel V, Wang H et al. Growth factor-sensitive molecular targets identified in primary and metastatic head and neck squamous cell carcinoma using microarray analysis. Oral Oncol.42(3), 240–256 (2006).
   PubMedGoogle Scholar
• Miyazaki H, Patel V, Wang H et al. Downregulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res.66(8), 4279–4284 (2006).
   PubMed Web of Science ®Google Scholar
• Delilbasi CB, Okura M, Iida S, Kogo M. Investigation of CXCR4 in squamous cell carcinoma of the tongue. Oral Oncol.40(2), 154–157 (2004).
   PubMedGoogle Scholar
• Wang J, Xi L, Hunt JL et al. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res.64(5), 1861–1866 (2004).
   PubMedGoogle Scholar
• Wang J, Zhang X, Thomas SM et al. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene24(38), 5897–5904 (2005).
   PubMed Web of Science ®Google Scholar
• Hoffmann TK, Bier H, Whiteside TL. Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol. Immunother.53(12), 1055–1067 (2004).
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev.24(1), 95–105 (2005).
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314(5796), 126–129 (2006).
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Wang G, Westwood JA et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther.13(16), 1971–1980 (2002).
   PubMed Web of Science ®Google Scholar
• Hillinger S, Yang SC, Batra RK et al. CCL19 reduces tumour burden in a model of advanced lung cancer. Br. J. Cancer94(7), 1029–1034 (2006).
   PubMed Web of Science ®Google Scholar
• Robinson SC, Scott KA, Wilson JL et al. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res.63(23), 8360–8365 (2003).
   PubMed Web of Science ®Google Scholar
• Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J. Immunol.172(5), 2853–2860 (2004).
   PubMed Web of Science ®Google Scholar
• Wente MN, Keane MP, Burdick MD et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett.241(2), 221–227 (2006).
   PubMed Web of Science ®Google Scholar
• Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science272(5263), 872–877 (1996).
   PubMed Web of Science ®Google Scholar
• De Clercq E. The bicyclam AMD3100 story. Nat. Rev. Drug Discov.2(7), 581–587 (2003).
   PubMed Web of Science ®Google Scholar
• Doranz BJ, Grovit-Ferbas K, Sharron MP et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med.186(8), 1395–1400 (1997).
   PubMed Web of Science ®Google Scholar
• Ichiyama K, Yokoyama-Kumakura S, Tanaka Y et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc. Natl Acad. Sci. USA100(7), 4185–4190 (2003).
   PubMed Web of Science ®Google Scholar
• Fujii N, Nakashima H, Tamamura H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin. Investig. Drugs12(2), 185–195 (2003).
   Google Scholar
• Vabeno J, Nikiforovich GV, Marshall GR. Insight into the binding mode for cyclopentapeptide antagonists of the CXCR4 receptor. Chem. Biol. Drug Des.67(5), 346–354 (2006).
   Google Scholar
• Zeng Z, Samudio IJ, Munsell M et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol. Cancer Ther.5(12), 3113–3121 (2006).
   PubMed Web of Science ®Google Scholar
• Burns JM, Summers BC, Wang Y et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med.203(9), 2201–2213 (2006).
   PubMed Web of Science ®Google Scholar
• Yeudall WA, Wrighton KH. Cell cycle deregulation in head and neck cancer. In: Head and Neck Cancer: Emerging Perspectives. Ensley JF, Gutkind JS, Jacobs JR, Lippmann SE (Eds). Academic Press, CA, USA 101–116 (2003).
   Google Scholar
• Snyder EL, Saenz CC, Denicourt C et al. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res.65(23), 10646–10650 (2005).
   PubMedGoogle Scholar
• Keane MM, Rubinstein Y, Cuello M et al. Inhibition of NF-κB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res. Treat.64(2), 211–219 (2000).
   PubMed Web of Science ®Google Scholar
• Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer2(4), 301–310 (2002).
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol.5(10), 749–759 (2005).
   PubMed Web of Science ®Google Scholar
• Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-κB in development and progression of human cancer. Virchows Arch.446(5), 475–482 (2005).
   PubMed Web of Science ®Google Scholar
• Singh S, Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med. Chem.6(3), 259–270 (2006).
   PubMedGoogle Scholar
• Hipp MS, Urbich C, Mayer P et al. Proteasome inhibition leads to NF-κB-independent IL-8 transactivation in human endothelial cells through induction of AP-1. Eur. J. Immunol.32(8), 2208–2217 (2002).
   PubMedGoogle Scholar
• Keshamouni VG, Arenberg DA, Reddy RC et al. PPAR-γ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia7(3), 294–301 (2005).
   PubMed Web of Science ®Google Scholar